The Role of Esketamine in the Treatment of TRD

Video
Experts on depression.

Merrideth Leggat, MD, reviews clinical and practical implications of findings from the TRANSFORM and SUSTAIN studies exploring the utility of esketamine in the treatment of TRD.

Related Videos
Manish Jha, MD: Treatment Options for Treatment-Resistant Depression
Katharine Phillips, MD: Differences Between OCD, Body Dysmorphic Disorder
Brian Barnett, MD: Psychedelics Fitting into the SUDs Treatment Paradigm
Lenard A. Adler, MD: “Symptoms of ADHD Need to Go Back to Childhood”
3 Barriers to Improving Clozapine Use in Treatment-Resistant Schizophrenia
Evaluating MM120 for GAD with Daniel Karlin, MD, and Reid Robinson, MD, MBA
Daniel Karlin, MD: Prevalence of Undiagnosed Generalized Anxiety Disorder
The Future of DSM-5-TR with APA Members Nitin Gogtay, Maria Oquendo, Jonathan Alpert
Paul Appelbaum, MD: What to Warn Patients When Prescribing Psychedelics in the Future
Related Content
James Rucker, PhD | Credit: King's College London

First Study of Psilocybin in PTSD Shows Promise, Safety of Treatment Approach

May 9th 2024
Article
The Physician Burnout Crisis, with Sue Padernacht, EDd, PCC

The Physician Burnout Crisis, with Sue Padernacht, EDd, PCC

January 11th 2024
Podcast
FDA Advisory Committee Meeting to Review MDMA-Assisted Therapy for PTSD

FDA Advisory Committee Meeting to Review MDMA-Assisted Therapy for PTSD

May 6th 2024
Article
John J. Miller, MD: A New Era For Psychiatric Medications

John J. Miller, MD: A New Era For Psychiatric Medications

August 18th 2022
Podcast
Schizophrenia Patients Face Longer Hospitalization Stays for Non-Psychiatric Conditions

Schizophrenia Patients Face Longer Hospitalization Stays for Non-Psychiatric Conditions

May 5th 2024
Article
Doxazosin Shows Potential as Alternative PTSD-Related Nightmare Treatment

Doxazosin Shows Potential as Alternative PTSD-Related Nightmare Treatment

May 5th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.